Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Cisplatin 3X-Rays 2zimberelimab 1dl1520 1Taxes 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiation 1Practice Guidelines as Topic 1Polymerase Chain Reaction 1Platinum 1Narrow Band Imaging 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Magnetic Resonance Spectroscopy 1Gene Expression Profiling 1Fluorouracil 1Drug Delivery Systems 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hypopharyngeal Neoplasms × Radiotherapy, Image-Guided × Clear all
NCT06084845 2024-07-25

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡